Role of TMEM219 Marker in Type 1 Diabetes

计划入组 60 人 · 首次发布于 2019 年 1 月 7 日

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants

计划入组 104 人 · 首次发布于 2026 年 2 月 19 日

IGFBP3/TMEM219 inhibitor(Enthera Srl)

Genetic Factors Drive Early B Cell Repletion After Anti-CD20 Therapy in African American MS Patients

Meiji Seika Pharma Launches Phase I Trial of ME3241, Novel PD-1 Agonist for Autoimmune Diseases